Bolt Bio (BOLT): Average Forecast Price
Bolt Biotherapeutics is optimizing expenses and shifting its strategic direction, focusing on accelerating trials for its primary oncology drug. The company is attracting leading specialists through a stock option system and unique developments. This price chart for shares on GURU.Markets captured the 48.34 indicator. The business creates cutting-edge immunotherapy agents that combine stimulants with antibodies to effectively destroy malignant tumors.
Analytical breakdowns for Bolt Biotherapeutics (BOLT)
- current price and projected stock value:
- stock exchange capitalization data:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Equity Bolt Biotherapeutics|BOLT - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital boltbio.com|BOLT - Company Aggregate Debts|Debts to Book Capitalization Bolt Bio|BOLT - Company Long-Term Debt|Company Short-Term Loans and Borrowings Bolt Biotherapeutics|Quick Liquidity Indicator boltbio.com
- financial results and valuation multiples details:
BOLT - Net Profit|Projected Future Earnings Bolt Biotherapeutics|BOLT - Price to Earnings Ratio|Future Price to Earnings Multiple boltbio.com|BOLT - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Bolt Bio|BOLT - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Bolt Biotherapeutics|BOLT - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months boltbio.com|BOLT - Net earnings per share growth this year|Earnings growth forecast for next year Bolt Biotherapeutics
General company analysis:BOLT Bolt Biotherapeutics Inc.
Professional managers utilize fundamental metrics to filter assets, assessing the average investment house expectation for the security's fair value. The price action of the market consensus target for Bolt Biotherapeutics (BOLT) reflects analysts' reactions to the liquidity and potential of the ISAC platform in tumor therapy, allowing investors to correlate the cost of Bolt Biotherapeutics (BOLT) innovations with real market risks and long-term oncology development goals.
Competitors of Bolt Biotherapeutics
Price Target Chart ARGX (argenx.com)|Price Target Chart BioNTech BNTX|Abivax SA (ABVX) - Average Forecast Price|ADMA - Price Target Chart|PTGX: Price Target Chart|IMVT (Immunovant, Inc.) - Consensus Target|KNSA: Analyst Forecast Prices|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|Aerovate - Analyst Consensus Forecast|ACRS: Price Target Chart|Kyverna Therapeutics (KYTX) - Price Target Chart|Average Forecast Price tizianalifesciences.com (TLSA)|Price Target Chart Cabaletta Bio|Price Target Chart VTYX|Consensus Target THTX (Theratechnologies Inc)|Analyst Forecast Prices AVTX|Eledon Pharmaceuticals - Consensus Target|Fair Value Consensus AGEN|Climb Bio - Analyst Consensus Forecast|ZURA: Price Target Chart|ATYR: Analyst Consensus Forecast|ADAG - Analyst Median Target|Price Target Chart ImageneBio|Average Forecast Price Shattuck Therapeutics STTK|Consensus Target EQ (Equillium, Inc.)|Analyst Forecast Prices CNTB|Analyst Consensus Forecast IMUX (Immunic)|Fair Value Consensus ATRA|InflaRx GmbH - Analyst Consensus Forecast|Average Forecast Price x4pharma.com|adicetbio.com (ACET) - Price Target Chart|Celularity - Fair Value Consensus|INMB (INmune Bio Corp) - Analyst Consensus Forecast|Analyst Consensus Forecast Barinthus Biotherapeutics Corp|Price Target Chart Kezar Life Sciences (KZR)|SABS: Forecast Levels Chart|Analyst Consensus Forecast AKTX (Akari Therapeutics Plc)|Enlivex Therapeutics Ltd (ENLV) - Average Forecast Price|QTTB: Consensus Target|GOVX - Analyst Consensus Forecast|EDSA (Edesa Biotech, Inc.) - Consensus Target|IBIO: Analyst Forecast Prices|CARM (Carisma Therapeutics Inc) - Analyst Consensus Forecast|XTL Biopharmaceuticals Ltd (XTLB) - Analyst Median Target|Analyst Consensus Forecast HCWB|Consensus Target aptevotherapeutics.com APVO|Price Target Chart AIM ImmunoTech AIM|Analyst Median Target Aditxt Inc. (ADTX)|GRI Bio - Analyst Consensus Forecast|XRTX: Price Target Chart|ReShape Lifesciences (HIND) - Price Target Chart|Average Forecast Price Revelation Biosciences Corp (REVB)|Price Target Chart Indaptus Therapeutics|Price Target Chart SCNI|Consensus Target CALI (CalciMedica, Inc.)|Analyst Forecast Prices AFMD|Price Target Chart Allakos ALLK|HOOK (HOOKIPA Pharma, Inc.) - Forecast Levels Chart|IGM Bio - Analyst Consensus Forecast|Fair Value Consensus ITOS (iteostherapeutics.com)|OCEA: Analyst Consensus Forecast|TC BioPharm (Holdings) Plc (TCBP) - Analyst Consensus Forecast|Price Target Chart Third Harmonic Bio, Inc
